Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Richard Greil, Sonja Burgstaller et al.|Blood|2015Cited by 186
Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg‐proline‐interferon alpha‐2bNicole C.C. Them, Róbert Královics, Klaudia Bagienski et al.|American Journal of Hematology|2014Cited by 54
Analysis Of Molecular Responses and Chromosomal Aberrations In Patients With Polycythemia Vera Treated With Peg-Proline-Interferon Alpha-2b (AOP2014/P1101) In The Peginvera StudyNicole C.C. Them, Róbert Královics, Heinz Gisslinger et al.|Blood|2013Cited by 3
Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera StudVeronika Buxhofer‐Ausch, Richard Greil, Heinz Gisslinger et al.|Blood|2015Cited by 1
Calreticulin Mutation Status Predicts Improved Disease Outcome in Prefibrotic Primary Myelofibrosis but Not in WHO-Defined Essential ThrombocythemiaHeinz Gisslinger, Róbert Královics, Jüergen Thiele et al.|Blood|2014Cited by 1